HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFRA Upholds 50 Years Of Risk Assessment, Scent ‘Essentiality’ In Green Deal Policy Recommendations

Executive Summary

Essentiality criteria for substances categorized as “most harmful” in the EU – which otherwise may be banned under the Chemicals Strategy for Sustainability – must take into account social and societal benefits, says the International Fragrance Association in recently published Green Deal policy recommendations.

You may also be interested in...



EU Sustainable Chemicals Program Could Impact 60% Of Fragrance Ingredients – Givaudan

Certain rose, jasmine, cedarwood, freesia, lavender, apple, orange and musk fragrance ingredients could be eliminated purely on the basis of hazard if EU sustainable chemical principles are implemented as discussed across sectors and regulatory programs, according to Givaudan’s Greg Adamson, senior VP, global regulatory affairs and product safety for fragrance and beauty.

EU Starts On Proposal For Tackling ‘Most Harmful’ Chemicals Under Revised Cosmetics Reg

The European Commission is preparing a legal proposal to revise the Cosmetic Products Regulation in line with Green Deal objectives, including the phasing out of chemicals deemed “most harmful." Cosmetics Europe director-general John Chave discusses the problematic approach, possible impacts, and the bizarre and unintended results it could produce.

European Commission Consults Public On Proposal To Revise Cosmetics Regulation

The Commission specifically cites “lack of specific provisions for endocrine disruptors, the applicability of a generic approach on risk management (GRA) for other harmful substances, the potential diverging opinions from committees responsible for the assessment of chemicals, and the lack of coherence between legislations on the definition of nanomaterials” as points of interest.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel